Relationships of Executive Functions, Severity of Psychiatric Symptoms With Response to Therapy
NCT04603170 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 164
Last updated 2020-10-28
Summary
This study was conducted to investigate the moderating role of executive functions in the relationship between the severity of psychiatric symptoms and response to therapy. The statistical population of this study was all outpatients with anxiety disorders and depression who referred to psychiatric clinics.
Conditions
- Patient Acceptance of Health Care
Interventions
- OTHER
-
DRUG
taking drug medication prescribed by psychiatrists for at least one month
Sponsors & Collaborators
-
Malahat Amani
lead OTHER
Principal Investigators
-
Malahat amani, ph.d · University of Bojnord
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-01-01
- Primary Completion
- 2019-02-01
- Completion
- 2019-03-01
Countries
- Iran
Study Locations
More Related Trials
-
Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients
NCT03451734 ·Status: COMPLETED
-
Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
NCT03784222 ·Status: TERMINATED ·Phase: PHASE4
-
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia
NCT04917302 ·Status: RECRUITING ·Phase: PHASE2
-
Study on the Role and Mechanism of Plasma Exosome microRNAs in Cognitive Impairment in First-episode Schizophrenia
NCT07139171 ·Status: RECRUITING
-
Functional Magnetic Resonance Imaging Study in Schizophrenia Patients and Correlation With Cognitive Impairments
NCT06471179 ·Status: NOT_YET_RECRUITING
-
Cognitive Strategies in Early Psychosis 1
NCT07231497 ·Status: RECRUITING ·Phase: PHASE3
-
tDCS and Executive Function Training for Schizophrenia
NCT05389345 ·Status: WITHDRAWN ·Phase: NA
-
Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity
NCT06315972 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study on Evaluation of Mental Health Index of Patients With Psychiatric Disorders
NCT00166764 ·Status: UNKNOWN
-
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
NCT00942981 ·Status: COMPLETED
-
Exercise Therapy in Mental Disorders-study
NCT06313918 ·Status: RECRUITING ·Phase: NA
-
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia
NCT05240976 ·Status: RECRUITING ·Phase: PHASE2
-
Effectiveness of Traditional Chinese Metacognitive Training (MCT) in Patients With Schizophrenia, Depression, or Bipolar Disorder Attending a Psychiatric Day Hospital in Taiwan
NCT07051746 ·Status: COMPLETED ·Phase: NA
-
Goals in Focus: CBT for Motivational Negative Symptoms of Psychosis
NCT05252039 ·Status: RECRUITING ·Phase: NA
-
Serotonin 1A Agonists and Cognition in Schizophrenia
NCT00178971 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacology of Cognition in Schizotypal Personality Disorder
NCT00353379 ·Status: TERMINATED ·Phase: PHASE4
-
Treating Psychotic Symptoms of Young Individuals Presenting a First Episode of Schizophrenia: Comparison of Two State-of-the-Art Interventions
NCT00358709 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating Pharmacogenomics-Based Pharmacotherapy in Real-World Settings for Schizophrenia
NCT06700967 ·Status: NOT_YET_RECRUITING
-
Effect of Memantine on ERP in Early Schizophrenia and Healthy Subjects
NCT02233556 ·Status: UNKNOWN ·Phase: NA
-
Goal Management Training for Patients With Schizophrenia or High Risk for Schizophrenia
NCT03048695 ·Status: COMPLETED ·Phase: NA
-
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
NCT06021197 ·Status: RECRUITING ·Phase: PHASE2
-
Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders
NCT04218981 ·Status: COMPLETED ·Phase: NA
-
Functional Brain Activation Patterns in Schizophrenia, Measured Before and After Treatment
NCT00161057 ·Status: COMPLETED
-
Metformin Treatment on Cognitive Impairment of Schizophrenia
NCT05838573 ·Status: RECRUITING ·Phase: PHASE3
-
Imagery Rescripting as a Treatment for Early Psychosis
NCT06539780 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA